# Harmony Biosciences Reports Record Q2 2026 Revenue and Shares First BP-205 Clinical Data

> news · REPORTED · 2026-08-04

Harmony Biosciences reported Q2 2026 WAKIX net product revenue of $261.3 million, up 30% year over year, with approximately 8,950 average patients, and reiterated full-year 2026 WAKIX net revenue guidance of $1.0 to $1.04 billion. The company also released Phase 1 single ascending dose data for its orexin-2 agonist BP-205, showing favorable pharmacokinetics and a clean safety and tolerability profile with no serious or severe treatment-emergent adverse events.

About Harmony Biosciences Holdings, Inc.: Harmony Biosciences is a pharmaceutical company that develops and commercializes therapies for patients with rare neurological diseases, including narcolepsy and idiopathic hypersomnia, with its lead commercial product WAKIX (pitolisant).

- Company: Harmony Biosciences Holdings, Inc.
- Sector: therapeutics
- Primary source: https://www.stocktitan.net/news/HRMY/

---
Source: MedFuel Intel news monitor. Verification tier: REPORTED. Informational only, not investment advice. Corrections: media@medfuelinc.com.